3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
31
INDUSTRY
15
OTHER_GOV
1
NIH
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
5
Esophageal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Pathologic Complete Response
2
Fallopian Tube Neoplasms
2
Adenocarcinoma of Lung
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Testicular Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Non-squamous Cell Non-Small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
HER2 Positive Breast Cancer
1
Endometrial Neoplasms
1
EGFR Positive Non-small Cell Lung Cancer
1
Carcinoma, Ovarian Epithelial
1
Interventions
Surgical Procedures, Operative
2
Dexamethasone
2
temoporfin
1
pomalidomide
1
pembrolizumab
1
nimotuzumab
1
liposomal doxorubicin
1
ledipasvir
1
ibrutinib
1
golimumab
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Thalidomide
1
Sofosbuvir
1
Rituximab
1
Ribavirin
1
Radiotherapy
1
Radiation
1
Paclitaxel
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mitoxantrone
1
Mastectomy
1
Irinotecan
1
Infliximab
1
Immunotherapy, Adoptive
1
Hematologic Tests
1
Drug Therapy
1
Docetaxel
1
Diagnostic Imaging
1
Dermoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Recurrence
×
Carboplatin
×
Clear all
NCT06670911
2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2
Recruiting
44 enrolled